SCHEMBL30285756

SCHEMBL30285756

O=C(Cc1ccc(F)cc1Cl)Nc1cnnc(Nc2ccccc2)c1

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ROCK2 O75116 1/20 0.44
▸ P2RX7 Q99572 7/20 0.44
▸ TP53 P04637 1/20 0.44
▸ KCNJ5 P48544 2/20 0.43
▸ KCNJ3 P48549 2/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ ACKR3 P25106 2/20 0.41
▸ RECQL P46063 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ MAPT P10636 1/20 0.41
▸ HPGD P15428 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ APOBEC3G Q9HC16 1/20 0.41
▸ HDAC3 O15379 1/20 0.40
▸ NCOR1 O75376 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26186447 1.00 ROCK2 (0.44) ROCK2P2RX7TP53KCNJ5KCNJ3
SCHEMBL30285728 0.94 ROCK2 (0.48) ROCK2P2RX7ALDH1A1ACKR3RECQL
SCHEMBL26186448 0.94 ROCK2 (0.48) ROCK2P2RX7ALDH1A1ACKR3RECQL
SCHEMBL26186457 0.93 SMN1; SMN2 (0.46) ROCK2P2RX7TP53KCNJ5KCNJ3
SCHEMBL30285736 0.93 SMN1; SMN2 (0.46) ROCK2P2RX7TP53KCNJ5KCNJ3
SCHEMBL30285795 0.90 ROCK2 (0.45) ROCK2P2RX7ALDH1A1SMN1; SMN2ACKR3
SCHEMBL26186464 0.90 ROCK2 (0.45) ROCK2P2RX7ALDH1A1SMN1; SMN2ACKR3
SCHEMBL30285528 0.88 KCNJ5 (0.50) ROCK2KCNJ5KCNJ3ALDH1A1SMN1; SMN2
SCHEMBL26186450 0.88 KCNJ5 (0.50) ROCK2KCNJ5KCNJ3ALDH1A1SMN1; SMN2
SCHEMBL30285692 0.88 KCNJ5 (0.56) ROCK2KCNJ5KCNJ3ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 — — CN claimed
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY BAYER AKTIENGESELLSCHAFT (DE) 2023-08-17 — — US disclosed
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230257351-A1 SUBSTITUTED N-PHENYLACETAMIDES HAVING P2X4 RECEPTOR ANTAGONISTIC ACTIVITY P2RX2, P2RX5, P2RX3 ROCK2 4776/4885P2RX7 6/4885TP53 1311/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback